journal article·2014

Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9

Manoj Kumar, Gurpal Singh, Sapna Sharma, Dikshi Gupta, Vivek Bansal, Vikas Arora, Madhusudan Bhat, Sandeep K. Srivastava, Sameer Sapra, Surender Kharbanda, Amit K. Dinda, Harpal Singh

Nanoscale· Volume 6· Issue 23
Publisher page

Abstract

Delivering peptides into cells targeting the undruggable oncoproteins is an emerging area in cancer therapeutics. Here we report a novel nanoparticle-based delivery system that can transport therapeutic cargos to the intracellular sites without the need for a cell transduction or penetration domain (CPP). In the present study, we have used iron oxide nanoparticles to deliver an oncopeptide, NuBCP-9, targeting the BCL-2 BH3 domain. Citric acid/2-bromo 2-methylpropanoic acid (CA/BMPA)-capped SPIONs were used to immobilize and deliver the NuBCP-9 peptide to the cancer cells without any noticeable off-target effects. Our results have demonstrated that NuBCP-9-SPIONs efficiently penetrate into cancer cells and bind to its intracellular target protein BCL-2. Moreover, significant inhibition of proliferation and substantial induction of cell death were observed when cancer cells were treated with NuBCP-9-SPIONs at different time intervals. Importantly, the IC50 values for killing of breast cancer cells with NuBCP-9-SPIONs were much lower compared to cells treated with the NuBCP-9 peptide linked with a CPP (Arg-8; NuBCP-9-R8). Molecular and biochemical analyses further supported that NuBCP-9-SPIONs killed breast cancer cells by apoptosis-mediated mechanisms. Furthermore, our data demonstrated that administration of NuBCP-9-SPIONs to mice bearing Ehrlich ascites tumors (EAT) was associated with loss of tumorigenicity and extensive apoptosis in tumor tissues. Taken together, these findings show that a non-CPP-tagged peptide can be successfully delivered to undruggable intracellular oncotargets using SPIONs.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoparticle-Based Drug Delivery · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Center for Biomedical Engineering

Indian Institute of Technology

Delhi,, India

Department of Chemistry

Department of Pathology

All India Institute of Medical Sciences Ansari Nagar

, India

Department of Medical Oncology

Dana-Farber Cancer Institute

Harvard Medical School

Boston, USA

References (60)

Show source-provided references
1. Ashkenazi · Nat. Rev. Drug Discovery · 2008 · 7 · 100110.1038/nrd2637 ↗
2. Borden · Nat. Rev. Drug Discovery · 2008 · 7 · 95910.1038/nrd2756 ↗
3. Cotter · Nat. Rev. Cancer · 2009 · 9 · 50110.1038/nrc2663 ↗
4. Yip · Oncogene · 2008 · 27 · 639810.1038/onc.2008.307 ↗
5. Szakacs · Nat. Rev. Drug Discovery · 2006 · 5 · 21910.1038/nrd1984 ↗
6. Oltersdorf · Nature · 2005 · 435 · 67710.1038/nature03579 ↗
7. Jones · Int. J. Pharm. · 2008 · 354 · 3410.1016/j.ijpharm.2007.10.046 ↗
8. Grdisa · Curr. Med. Chem. · 2011 · 18 · 137310.2174/092986711795029591 ↗
9. Foged · Expert Opin. Drug Delivery · 2008 · 5 · 10510.1517/17425247.5.1.105 ↗
10. Kolluri · Cancer Cell · 2008 · 14 · 28510.1016/j.ccr.2008.09.002 ↗
11. Luciano · Blood · 2007 · 109 · 384910.1182/blood-2006-11-056879 ↗
12. Watkins · Mol. Ther. · 2011 · 19 · 212410.1038/mt.2011.175 ↗
13. Manzoor · Cancer Res. · 2012 · 72 · 556610.1158/0008-5472.CAN-12-1683 ↗
14. Matsumura · Cancer Res. · 1986 · 46 · 6387
15. Gref · Science · 1994 · 263 · 160010.1126/science.8128245 ↗
16. Zhang · Cancer Res. · 2009 · 69 · 650610.1158/0008-5472.CAN-08-4721 ↗
17. Vila · J. Controlled Release · 2002 · 78 · 1510.1016/S0168-3659(01)00486-2 ↗
18. Lee · Chem. Soc. Rev. · 2012 · 41 · 265610.1039/C2CS15261D ↗
19. Bulte · NMR Biomed. · 2004 · 17 · 48410.1002/nbm.924 ↗
20. Jedlovszky-Hajdu · J. Magn. Magn. Mater. · 2012 · 324 · 317310.1016/j.jmmm.2012.05.031 ↗
21. Sonvico · Bioconjugate Chem. · 2005 · 16 · 118110.1021/bc050050z ↗
22. Zhang · Acta Biomater. · 2008 · 4 · 4010.1016/j.actbio.2007.06.006 ↗
23. Hwu · J. Am. Chem. Soc. · 2009 · 131 · 6610.1021/ja804947u ↗
24. Wu · Chem. – Eur. J. · 2007 · 13 · 387810.1002/chem.200601372 ↗
25. Chomoucka · Pharmacol. Res. · 2010 · 62 · 14410.1016/j.phrs.2010.01.014 ↗
26. Mahmoudi · Adv. Drug Delivery Rev. · 2011 · 63 · 2410.1016/j.addr.2010.05.006 ↗
27. Sun · Adv. Drug Delivery Rev. · 2008 · 60 · 125210.1016/j.addr.2008.03.018 ↗
28. Tran · J. Mater. Chem. · 2010 · 20 · 876010.1039/c0jm00994f ↗
29. Kumar · Int. J. Nanomed. · 2012 · 7 · 3503
30. Nathan · Ann. Oncol. · 1994 · 5 · 40910.1093/oxfordjournals.annonc.a058871 ↗
31. Tan · Chem. Biodiversity · 2009 · 6 · 110110.1002/cbdv.200800141 ↗
32. Bhattacharyya · Carcinogenesis · 2003 · 24 · 7510.1093/carcin/24.1.75 ↗
33. Zhang · Biomaterials · 2012 · 33 · 218710.1016/j.biomaterials.2011.11.045 ↗
34. Yu · Angew. Chem., Int. Ed. · 2008 · 47 · 536210.1002/anie.200800857 ↗
35. Jain · Mol. Pharm. · 2008 · 5 · 31610.1021/mp7001285 ↗
36. Verdine · Clin. Cancer Res. · 2007 · 13 · 726410.1158/1078-0432.CCR-07-2184 ↗
37. Plescia · Cancer Cell · 2005 · 7 · 45710.1016/j.ccr.2005.03.035 ↗
38. Sarafraz-Yazdi · Proc. Natl. Acad. Sci. U. S. A. · 2010 · 107 · 191810.1073/pnas.0909364107 ↗
39. Moellering · Nature · 2009 · 462 · 18210.1038/nature08543 ↗
40. Raina · Mol. Cancer Ther. · 2011 · 10 · 80610.1158/1535-7163.MCT-10-1050 ↗
41. Grossmann · Proc. Natl. Acad. Sci. U. S. A. · 2012 · 109 · 1794210.1073/pnas.1208396109 ↗
42. Stewart · Nat. Chem. Biol. · 2010 · 6 · 59510.1038/nchembio.391 ↗
43. Lin · Cell · 2004 · 116 · 52710.1016/S0092-8674(04)00162-X ↗
44. Fischer · Med. Res. Rev. · 2007 · 27 · 75510.1002/med.20093 ↗
45. Kamaly · Chem. Soc. Rev. · 2012 · 41 · 297110.1039/c2cs15344k ↗
46. Xiao · Int. J. Nanomed. · 2010 · 5 · 1057
47. Kumar · Cancer Res. · 2014 · 74 · 327110.1158/0008-5472.CAN-13-2015 ↗
48. Laurent · Chem. Rev. · 2008 · 108 · 206410.1021/cr068445e ↗
49. Veiseh · Adv. Drug Delivery Rev. · 2010 · 62 · 28410.1016/j.addr.2009.11.002 ↗
50. Jain · Mol. Pharm. · 2005 · 2 · 19410.1021/mp0500014 ↗
51. Mody · Appl. Nanosci. · 2014 · 4 · 38510.1007/s13204-013-0216-y ↗
52. Agemy · Proc. Natl. Acad. Sci. U. S. A. · 2011 · 108 · 1745010.1073/pnas.1114518108 ↗
53. Singh · J. Nanosci. Nanotechnol. · 2011 · 11 · 383410.1166/jnn.2011.4169 ↗
54. You · Nanotechnology · 2008 · 19
55. Brahatheeswaran · Biomed. Mater. · 2012 · 7
56. Zhou · Mater. Sci. Eng., C · 2006 · 26 · 145110.1016/j.msec.2005.08.027 ↗
57. Tomayko · Cancer Chemother. Pharmacol. · 1989 · 24 · 14810.1007/BF00300234 ↗
58. Euhus · J. Surg. Oncol. · 1986 · 31 · 22910.1002/jso.2930310402 ↗
59. Liu · Nanoscale · 2012 · 4 · 230610.1039/c2nr11918h ↗
60. Jacobs · J. Clin. Oncol. · 1999 · 17 · 197410.1200/JCO.1999.17.7.1974 ↗